Story Summary: Increasing interest, new collaborations and breakthrough advancements led Santaris Pharma A/S, headquartered in Denmark, to establish US-based operations in San Diego, California. He received a law degree from Thomas Jefferson School of Law, San Diego, California, and a B. A. from Valparaiso University, Valparaiso, Indiana. Mr. Mackey joins Santaris Pharma A/S after spending the last ten years at leading biotech company Amgen Inc. where most recently he was Managing Director of Amgen Ventures, a $100 M venture capital affiliate of Amgen Inc. with approximately 15 portfolio companies. He had also been responsible for Amgens in- and outlicensing transactions group and Amgens Corporate Alliance Management function. The drug SPC3649 specifically targets microRNA-122 (miR-122), a host factor for Hepatitis C virus replication. Santaris Pharma A/S recently announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-targeted medicines to treat rare genetic disorders. About Locked Nucleic Acid (LNA) Drug PlatformThe Locked Nucleic Acid (LNA) Drug Platform developed by Santaris Pharma A/S creates synthetically modified chemical versions of the normal nucleic acid building blocks of ribonucleic acids (RNA). These modified chemical versions called LNAs improve the drug-like qualities of resulting therapeutics (oligonucleotides) by boosting resistance to metabolism, increasing half-life and improving tissue uptake. The Companys own research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases. The Companys own research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the US. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the US. Please visit www. Media Contacts: Navjot Rai Randi Krogsgaard Santaris Pharma A/S, USA Santaris Pharma A/S, Denmark Office: +1-858-764-7066 ext….Read the Full Story

Related posts:

1. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
2. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
3. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
4. Santaris Pharma A/S :: LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
5. Santaris Pharma A/S :: Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule